​

Tandem Diabetes Care (TNDM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TNDM Stock Forecast

Tandem Diabetes Care (TNDM) stock forecast, based on 39 Wall Street analysts, predicts a 12-month average price target of $29.95, with a high of $55.00 and a low of $15.50. This represents a 95.50% increase from the last price of $15.32.

$15 $23 $31 $39 $47 $55 High: $55 Avg: $29.95 Low: $15.5 Last Closed Price: $15.32

TNDM Stock Rating

Tandem Diabetes Care stock's rating consensus is Buy, based on 39 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 24 Buy (61.54%), 15 Hold (38.46%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 39 0 15 24 Strong Sell Sell Hold Buy Strong Buy

TNDM Price Target Upside V Benchmarks

TypeNameUpside
StockTandem Diabetes Care95.50%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks28.49%

Price Target Trends

1M3M12M
# Anlaysts1626
Avg Price Target$15.50$31.25$27.67
Last Closing Price$15.32$15.32$15.32
Upside/Downside1.17%103.98%80.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 263911--23
May, 263911--23
Apr, 263911--23
Mar, 262814--24
Feb, 262713-123
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 23, 2026Deutsche Bank$15.50$14.348.09%1.17%
Jun 01, 2026Wells Fargo$27.00$17.2056.98%76.24%
May 27, 2026Goldman Sachs$21.00$14.5444.43%37.08%
May 11, 2026Barclays$55.00$15.48255.30%259.01%
May 08, 2026Anthony PetroneMizuho Securities$24.00$18.4729.94%56.66%
Apr 24, 2026Issie KirbyRedburn Partners$45.00$20.68117.60%193.73%
Feb 23, 2026Truist Financial$27.00$24.579.89%76.24%
Feb 23, 2026Lake Street$50.00$24.57103.50%226.37%
Feb 23, 2026David RomanGoldman Sachs$28.00$24.5713.96%82.77%
Feb 23, 2026Matt MiksicBarclays$56.00$24.57127.92%265.54%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 23, 2026Deutsche BankHoldinitialise
Jun 01, 2026Wells FargoBuyOverweightupgrade
May 28, 2026CitigroupNeutralNeutralhold
May 11, 2026BenchmarkHoldinitialise
Apr 20, 2026Cowen & Co.BuyBuyhold
Feb 23, 2026Lake StreetHoldBuyupgrade
Feb 23, 2026Goldman SachsNeutralNeutralhold
Feb 23, 2026BarclaysOverweightOverweighthold
Feb 20, 2026UBSNeutralNeutralhold
Feb 20, 2026Bank of America SecuritiesNeutralupgrade

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.25$-1.47$-3.43$-1.47$-3.04---
Avg Forecast$0.30$-1.09$-3.21$-1.69$-1.22$-0.76$-0.27$-0.07
High Forecast$0.32$-1.07$-2.99$-1.35$-0.78$-0.19$0.34$-0.06
Low Forecast$0.30$-1.13$-3.39$-1.77$-1.43$-1.08$-0.66$-0.07
Surprise %-16.67%34.86%6.85%-13.02%149.18%---

Revenue Forecast

$650M $800M $950M $1B $1B $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$702.80M$801.22M$747.72M$940.20M$1.01B---
Avg Forecast$691.83M$802.00M$764.45M$909.25M$1.01B$1.13B$1.25B$1.37B
High Forecast$726.08M$823.70M$768.90M$935.20M$1.03B$1.13B$1.27B$1.40B
Low Forecast$678.59M$790.66M$755.55M$902.72M$999.97M$1.12B$1.23B$1.34B
Surprise %1.59%-0.10%-2.19%3.40%0.32%---

Net Income Forecast

$-350M $-270M $-190M $-110M $-30M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$15.57M$-94.59M$-222.61M$-96.03M$-204.71M---
Avg Forecast$20.84M$21.80M$-222.61M$-101.26M$-78.17M$-44.51M$-14.71M$-4.22M
High Forecast$27.73M$29.60M$-135.07M$-87.83M$-50.98M$-12.35M$22.31M$-4.13M
Low Forecast$13.95M$13.99M$-310.15M$-114.70M$-92.69M$-70.45M$-43.04M$-4.35M
Surprise %-25.30%-533.97%--5.17%161.88%---

TNDM Forecast FAQ

Is Tandem Diabetes Care stock a buy?

Tandem Diabetes Care stock has a consensus rating of Buy, based on 39 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 24 Buy, 15 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Tandem Diabetes Care is a favorable investment for most analysts.

What is Tandem Diabetes Care's price target?

Tandem Diabetes Care's price target, set by 39 Wall Street analysts, averages $29.95 over the next 12 months. The price target range spans from $15.5 at the low end to $55 at the high end, suggesting a potential 95.50% change from the previous closing price of $15.32.

How does Tandem Diabetes Care stock forecast compare to its benchmarks?

Tandem Diabetes Care's stock forecast shows a 95.50% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (28.49%).

What is the breakdown of analyst ratings for Tandem Diabetes Care over the past three months?

  • June 2026: 13.04% Strong Buy, 39.13% Buy, 47.83% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 13.04% Strong Buy, 39.13% Buy, 47.83% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 13.04% Strong Buy, 39.13% Buy, 47.83% Hold, 0% Sell, 0% Strong Sell.

What is Tandem Diabetes Care’s EPS forecast?

Tandem Diabetes Care's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.76, marking a -75.00% decrease from the reported $-3.04 in 2025. Estimates for the following years are $-0.27 in 2027, and $-0.07 in 2028.

What is Tandem Diabetes Care’s revenue forecast?

Tandem Diabetes Care's average annual revenue forecast for its fiscal year ending in December 2026 is $1.13B, reflecting a 10.90% increase from the reported $1.01B in 2025. The forecast for 2027 is $1.25B, and $1.37B for 2028.

What is Tandem Diabetes Care’s net income forecast?

Tandem Diabetes Care's net income forecast for the fiscal year ending in December 2026 stands at $-44.508M, representing a -78.26% decrease from the reported $-205M in 2025. Projections indicate $-14.707M in 2027, and $-4.223M in 2028.